We are currently experiencing technical issues due to the Microsoft outage. This will affect delivery of multi-factor authentication emails, invoice emails and service emails. We apologise for the disruption.

Explore 3 Stock Ideas & Industry Insights Download Free Report

Company price
0.0016 USD 0.00 ( 14.29%)
Last update at 2026-11-12T14:30:00Z
VOLUME
2600
Market Cap
0.71M

Momentum Score

…

Halberd Corporation, a biotech company, develops treatments for neurodegenerative diseases. It offers treatments for post traumatic stress disorder/chronic traumatic encephalopathy, Alzheimer's and Parkinson's disease, cancer, blood-borne, and cerebrospinal fluid related diseases. The company was incorporated in 2009 and is based in Jackson Center, Pennsylvania.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
0.00
Low
0.00
High
52 Week Price Range
0.00
Low
0.00
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High
AI Summary

Tykhe Corp (HALB.US) is an OTC Pink-listed company for which comprehensive public disclosures and audited filings are scarce, so its core business activities are not clearly documented in major regulatory sources. Because of that lack of transparency, long-term growth drivers are uncertain and the stock may appeal primarily to speculative investors seeking exposure to an early-stage or thinly traded issuer.

Risk Score
High

Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.

Key Metrics*

Previous Close
0.00
Dividend Yield
-
Revenue TTM
0.01M
Revenue Per Share
-
Gross Profit TTM
0.00M
Debt / Equity
-0.16
ROE
-
Net Debt
0.15M
ROCE
2.45%
Diluted EPS TTM
-

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-07-31 2024-07-31 2023-07-31 2022-07-31 2021-07-31
Type yearly yearly yearly yearly yearly
Date 2025-07-31 2024-07-31 2023-07-31 2022-07-31 2021-07-31
Income before tax -0.02M -0.08M -0.45M -1.62M -
Net income -0.02M -0.08M -0.45M -1.62M -
Selling general administrative - - 0.15M 0.71M -
Gross profit -0.00M -0.00M 0.00M 0.01M -
Reconciled depreciation - - 0.00M 0.00M -
Ebit -0.02M -0.08M -0.45M -1.62M -0.94M
Ebitda -0.02M -0.07M -0.45M -1.62M -
Depreciation and amortization 0.00M 0.00M 0.00M 0.00M -
Operating income -0.02M -0.08M -0.45M -1.62M -
Other operating expenses 0.02M 0.08M 0.45M 1.63M -
Interest expense 0.00M 0.00M 0.01M 0.01M 0.00M
Net interest income - - -0.01M -0.01M -
Total revenue - 0.00M 0.00M 0.01M -
Total operating expenses 0.02M 0.07M 0.45M 1.63M -
Cost of revenue 0.00M 0.00M 0.00M 0.00M -
Total other income expense net -0.00M -0.00M -0.01M -0.01M -
Net income from continuing ops - - -0.45M -1.62M -
Net income applicable to common shares - - - - -0.96M
Breakdown 2025-07-31 2024-07-31 2023-07-31 2022-07-31 2021-07-31
Type yearly yearly yearly yearly yearly
Date 2025-07-31 2024-07-31 2023-07-31 2022-07-31 2021-07-31
Total assets 0.00M 0.01M 0.01M 0.02M -
Other current assets 0.00M 0.00M - - -
Total liab 0.92M 0.73M 0.94M 0.75M -
Total stockholder equity -0.91M -0.72M -0.93M -0.73M -
Other current liab 0.20M 0.19M 0.21M 0.22M 0.22M
Common stock 0.06M 0.06M 0.06M 0.05M 0.05M
Capital stock - - 0.06M 0.05M -
Retained earnings -7.00M -6.98M -6.90M -6.44M -4.82M
Cash - 0.01M 0.01M 0.01M -
Total current liabilities 0.77M 0.58M 0.79M 0.60M 0.40M
Net debt 0.15M 0.14M 0.14M 0.14M -
Short long term debt total 0.15M 0.15M 0.15M 0.15M -
Other stockholder equity 6.02M 6.20M 5.91M 5.66M -
Property plant equipment - - - - 0.00M
Total current assets 0.00M 0.01M 0.01M 0.01M 0.06M
Net tangible assets - - - - -0.49M
Long term debt - - 0.15M 0.15M -
Accounts payable 0.57M 0.39M 0.58M 0.38M 0.18M
Non currrent assets other - 0.00M - - -
Non current assets total 0.00M 0.00M 0.00M 0.00M -
Breakdown 2024-07-31 2023-07-31 2022-07-31 2021-07-31 2020-07-31
Type yearly yearly yearly yearly yearly
Date 2024-07-31 2023-07-31 2022-07-31 2021-07-31 2020-07-31
Investments - 0.00M -0.00M - -
Change to liabilities - - - 0.17M 0.01M
Total cashflows from investing activities - - - -0.00M -0.00M
Net borrowings - - - 0.15M 0.15M
Total cash from financing activities 0.05M 0.24M 0.89M 0.82M 0.04M
Change to operating activities - - - -0.01M -0.00M
Net income -0.08M -0.45M -1.62M -0.96M -1.65M
Change in cash -0.00M -0.00M -0.03M 0.04M 0.00M
Begin period cash flow 0.01M 0.01M 0.04M - -
End period cash flow 0.01M 0.01M 0.01M 0.04M -
Total cash from operating activities -0.05M -0.24M -0.92M -0.79M -0.04M
Issuance of capital stock - 0.24M 0.89M - -
Depreciation 0.00M 0.00M 0.00M - -
Other cashflows from financing activities - - -0.00M - -
Change to netincome - - - 0.02M 1.60M
Capital expenditures 0.00M 0.00M 0.00M 0.00M 0.00M
Change in working capital 0.03M 0.21M 0.22M - -
Other non cash items - - 0.48M - -
Free cash flow -0.05M -0.24M -0.92M - -

Peer Comparison*

Sector: Healthcare Industry: Biotechnology

Stock Name
Change
(USD)
Price
(USD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to Revenue (x)
Enterprise Value
to EBITDA (x)
HALB
Tykhe Corp
0.00
14.29%
0.00 - - 101.93 16.90 472.90 -3.50
NVO
Novo Nordisk A/S
-0.54
1.32%
40.55 41.58 31.15 2.13 32.99 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc
-2.37
0.43%
544.66 30.22 24.27 10.36 6.50 9.99 24.66
REGN
Regeneron Pharmaceuticals Inc
-2.77
0.29%
956.64 29.07 20.12 7.57 3.82 6.95 19.42
ARGNF
argenx SE
-
-%
900.30 45.77 31.25 13.84 7.12 11.38 36.06

Profile*

Tykhe Corp

Halberd Corporation, a biotech company, develops treatments for neurodegenerative diseases. It offers treatments for post traumatic stress disorder/chronic traumatic encephalopathy, Alzheimer's and Parkinson's disease, cancer, blood-borne, and cerebrospinal fluid related diseases. The company was incorporated in 2009 and is based in Jackson Center, Pennsylvania.

PO Box 25, Jackson Center, PA, United States, 16133

814 786 8849

Name Title Year Born
Mr. William A. Hartman Pres, CEO & Chairman 1942
Mr. John S. Borza AVS, MBA, PE COO & Director 1954
Ms. Heidi H. Carl Director & Accounting Director 1971
Dr. Mitchell S. Felder M.D. CTO & Member of the Scientific Advisory Board 1954
Dr. Patricio F. Reyes FAAN, M.D. Chief Mechanical Officer & Member of the Scientific Advisory Board 1947
Mr. William A. Hartman President, CEO & Chairman 1942

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Support

Hi! How can we help you today?

Loading…